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Background: Liver transplantation is an important treatment option for patients with liver-originated tumors
including biliary tract carcinomas (BTCs). Post-transplant tumor recurrence remains a limiting factor for long-term
survival. The mammalian target of rapamycin-targeting immunosuppressive drug rapamycin could be helpful in
lowering BTC recurrence rates. Therein, we investigated the antiproliferative effect of rapamycin on BTC cells and
compared it with standard immunosuppressants.
Methods: We investigated two human BTC cell lines. We performed cell cycle and proliferation analyses after
treatment with different doses of rapamycin and the standard immunosuppressants, cyclosporine A and tacrolimus.
Results: Rapamycin inhibited the growth of two BTC cell lines in vitro. By contrast, an increase in cell growth was
observed among the cells treated with the standard immunosuppressants.
Conclusions: These results support the hypothesis that rapamycin inhibits BTC cell proliferation and thus might be
the preferred immunosuppressant for patients after a liver transplantation because of BTC.
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Biliary tract carcinoma (BTC) is the second most malig-
nant liver tumor and one of the 10 most frequent
gastrointestinal carcinomas worldwide, causing high
numbers of fatalities annually [1,2]. Despite all available
treatment options, the five-year survival rate of patients
with BTC is less than 20% [3,4].
Liver transplantation (LT) is a therapeutic option for
treatment of malignant liver tumors, including extrahepa-
tic BTC. It is a treatment modality, besides liver resection,
that offers a curative effect [5-9]. However, post-transplant
outcome after LT is hampered by recurrence of the pri-
mary disease, especially in the case of tumor recurrence
[10]. Tumor characteristics in the explanted liver that
characterize a ‘high-risk’ pathology, such as a poorly differ-
entiated tumor or vascular invasion, are widely accepted
predictors of a poor prognosis. Hence, there is ongoing* Correspondence: matthias.heuer@uk-essen.de
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reproduction in any medium, provided the orinterest into research on the impact of immunosuppres-
sive drugs upon tumor recurrence. The ideal immuno-
suppressive agent would simultaneously act as an
immunosuppressive agent while exhibiting antitumor
properties. In initial studies, rapamycin has been
suggested to be a promising immunosuppressant in
this regard [11-13]. It appears to be an alternative
to the standard immunosuppressive agents, that is,
the calcineurin inhibitors cyclosporine A and tacro-
limus. In addition to a comparable immunosuppres-
sive effect, rapamycin has also shown to impart an
antiproliferative effect in vitro [14,15]. As such, it is
of particular interest as an immunosuppressant for
patients undergoing LT for treatment of liver-
originated tumors like BTC.
Rapamycin, a macrocyclic lactone isolated from Strep-
tomyces hygroscopicus, has its own unique mechanism of
action. By binding to FK-binding protein 12, it inhibits
the functioning of a specific cell regulation protein of
cell growth, the mammalian target of rapamycin
(mTOR), which causes reduced phosphorylation of p70
S6 kinase further down the signal transduction pathwaytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is critical for the coordination of cellular events required
for progression from the G1 to the S phase of the cell
cycle. This appears to be directly related to the observed
antiproliferative effect in tumor cells, which is more or
less prominent depending on the pathological BTC sub-
type and the degree of differentiation. The magnitude of
this antiproliferative effect appears to vary with different
tumor cells and its subsets [8]. Likewise, the correlation
between the rapamycin dosages used and the growth-
inhibiting effect is not fully understood; especially in the
BTC tumor entities.
The aim of this study was to assess the effect of rapamy-
cin on tumor growth of different BTC cell lines in com-
parison with the standard immunosuppressive drugs. We
demonstrate an antiproliferative effect of different doses
of rapamycin on BTC cells, taking into account the estab-
lished concentrations of rapamycin generally used for
in vitro and in vivo studies.
Methods
Cell lines and culture modalities
Two human BTC cell lines, EGI-1 and TFK-1, obtained
from the German Collection of Microorganisms and Cell
Cultures, were used in this study [21]. The cell line EGI-1Figure 1 Proliferation assays showing the division index mean counts
described. Rapa = rapamycin. (*P <0.013 versus control).was cultured in Dulbecco’s Modified Eagle Medium sup-
plemented with 10% fetal calf serum, l-glutamine, penicil-
lin and streptomycin, while TFK-1 was grown in Roswell
Park Memorial Institute medium using the same
supplements.
Drugs
Rapamycin was acquired from Wyeth-Pharma
(Muenster, Westphalia, Germany), cyclosporine A
and tacrolimus were purchased from LC Laboratories
(Woburn, MA, USA). All drugs were exclusively dis-
solved in dimethyl sulfoxide to create a stock solu-
tion. The final concentrations were achieved by
diluting the stock solution in culture medium. The
most commonly used calcineurin inhibitor doses
were selected for the in vitro studies according to
physiological efficacy and current recommendations.
Proliferations assays and fluorescence-activated cell
sorting analysis
To examine cell count, cell proliferation and DNA syn-
thesis (fluorescence-activated cell sorting analysis,
FACS), two different standardized staining methods, car-
boxyfluorescein diacetate succinimidyl ester (CFSE) and
5-bromo-20-deoxyuridine (BrdU), were performed.of three experiments. Cells were exposed to rapamycin as
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mately 105 cells per well in 5 mL culture medium). After
24 hours, cells were treated with vehicle or different
concentrations of immunosuppressants (rapamycin: 1, 5,
10, 20 and 50 ng/mL; cyclosporine A: 10 ng/mL; tacroli-
mus: 25 ng/mL). After 48 hours of incubation, cells were
stained according to BrdU- and CFSE-protocols. Subse-
quently, fixed CFSE-stained cells (after incubation with
2.5 μg/mL RNase and then 2.5 μg/mL propidium iodide
solution) as well as 20,000 BrdU-stained cells were ana-
lyzed using a FACS scan flow cytometer (Becton-Dickinson,
NJ, USA). All FACS data sets were analyzed and calculated
with Win MDI Version 2.8 (Josef Trotter, The Scripps
Institute, Flow Cytometry Core Facility) and FlowJo Version
7.6.5 (Treestar, www.flowjo.com).
Statistical analyses
Data are expressed as the mean ± standard error of the
mean. and represent at least three independent experi-
ments. Following incubation with vehicle or immuno-
suppressants, FACS analysis was used to determine the
division index after a 24-hour period. One-way analysis
of variance was used for statistical analyses of the prolif-
erations assays. Differences were considered as signifi-
cant at levels of P < 0.05.Figure 2 Proliferation assays showing the division index from mean c
cyclosporine A. FK: tacrolimus; CsA: cyclosporine A.Results
Cell proliferation analyses
The cells were treated with immunosuppressants for 24
or 48 hours (Figure 1). The low differentiated BTC cell
line EGI-1 showed a homogenous inhibition of the div-
ision index in the rapamycin group. The strongest anti-
proliferative effect was observed at hour 48. Here, cell
growth was reduced by 8.5 to 12.4% (P= 0.001).
A similar result was observed in the TFK-1 cells treated
with rapamycin. In this BTC cell line, the division index
found in the control groups (with the exception of 1 ng/mL
rapamycin after 24 hours) was always above those of groups
treated with rapamycin. As in EGI-1 cells, non-significant
differences in growth inhibition between the respective
dosages 5, 10, 20 and 50 ng/mL were observed in
the TFK-1 cells.
This examination was completed by repeating the same
measurements with the standard immunosuppressants
cyclosporine A and tacrolimus. In contrast to the constant
antiproliferative effect of rapamycin, both standard immu-
nosuppressants caused a noticeable increase in BTC cell
growth (Figure 2) in some cases. Tacrolimus increased cell
growth in the low differentiated cell line EGI-1 by 8.6%,
while cyclosporine A-treated cells exhibited a growth rate
decrease of 4.6% after 24 hours of incubation. In TFK-1ounts of three experiments. Cells were treated with tacrolimus or
Table 1 Percentages of EGI-1 in each phase of the cell cycle after 48 hours of exposure to different dosages of
rapamycin
Group Apoptosisa G0/G1 phase G2+M phase S phase
Mean ±SE Pb Mean ±SE Pb Mean ±SE Pb Mean ±SE Pb
control 0.24 0.04 32.56 1.01 22.44 0.52 25.44 0.85
rapa 1 ng/mL 0.28 0.02 0.33 35.98 1.21 0.55 21.24 0.35 0.085 17.96 0.23 <0.001
rapa 5 ng/mL 0.30 0.02 0.21 38.77 1.28 <0.05 22.21 0.26 0.70 19.97 0.44 <0.001
rapa 10 ng/mL 0.52 0.04 <0.05 37.09 0.50 <0.05 24.45 0.70 <0.05 15.88 0.29 <0.001
rapa 20 ng/mL 0.55 0.04 <0.05 36.75 1.32 <0.05 23.31 0.45 0.23 14.56 0.33 <0.001
rapa 50 ng/mL 0.42 0.05 <0.05 33.16 0.44 0.60 26.05 0.14 <0.05 16.15 0.37 <0.001
Cell cycle analysis of EGI-1 and TFK-1 cell lines 48 hours after treatment with rapamycin at doses of 1, 5, 10 and 20 ng/mL, with 5-bromo-20-deoxyuridine and 7-
aminoactinomycin D staining aSub G1-region, indicating cells with small DNA fragments, a typical feature of apoptosis; bt-test was performed; while a Levene test
was performed in case of unequal variances, P <0.05 was considered significant. Rapa: rapamycin; SE: standard error of the mean.
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noticeably higher in tacrolimus-treated cells compared
with the control and cyclosporine A group.
Cell cycle analyses
These studies were carried out to further analyze the
biological basis of the immunosuppressant’s mechan-
isms of action. Tables 1 and 2 show the various
phases of the cell generation cycle after treatment
with the immunosuppressants.
Among the rapamycin-treated EGI-1 cells, only a mild
increase in the G0/G1 phase was observed as compared
with the control group, whereas among TFK-1 cells, the
G0/G1 phase was increased up to 37% (51.75% versus
37.78%; P ≤0.001). TFK-1 cells treated with tacrolimus
and cyclosporine A, respectively, especially showed a
decrease in the G1 phase. At the same time, an increase
in the S phase and an increase in DNA synthesis were
observed in those cells.
Moreover, rapamycin-treated EGI-1 cells displayed a
significant increase in apoptosis. Additionally, in both
cell types, the synthesis rate (S phase) clearly dropped.
The strongest decrease of the synthesis rate (14.56% ver-
sus 25.44%; P ≤0.001) was observed in the EGI-1 cellTable 2 Percentages of TFK-1 in each phase of the cell cycle a
rapamycin
Group Apoptosisa G0/G1 phase
Mean ±SE Pb Mean ±SE
control 0.15 0.03 37.78 1.67
rapa 1 ng/mL 0.11 0.02 0.21 51.75 1.07 <
rapa 5 ng/mL 0.09 0.01 <0.05 50.74 1.31 <
rapa 10 ng/L 0.08 0.01 <0.05 49.53 1.15 <
rapa 20 ng/mL 0.15 0.01 0.92 47.26 1.10 <
rapa 50 ng/mL 0.19 0.02 0.25 49.86 2.17 <
Cell cycle analysis of EGI-1 and TFK-1 cell lines 48 hours after treatment with rapam
aminoactinomycin D staining. aSub G1-region, indicating cells with small DNA fragm
was performed in case of unequal variances, P <0.05 was considered significant. rapline at a dose of 20 ng/mL rapamycin. Conversely, a
marked increase in the rate of synthesis and a decrease
in the apoptosis rate of TFK-1 cells were observed in
tacrolimus-treated cells. An increase of mitotic cells was
even more pronounced in cyclosporine A-treated TFK-1
cells.
Discussion
It is not yet clear how important the role of immunosup-
pression is in the development of post-transplant BTC
recurrences. Some investigators consider the majority of
the recurrences to be related to metastatic disease that
either was present but unidentifiable prior to transplant-
ation or was caused during the transplant procedure [8].
Other studies indicate that proper immunosuppression
management can stabilize the recurrence rate (for
example, in hepatocellular carcinoma cell lines) at a sat-
isfactory level [22,23]. Our study clearly demonstrates
that rapamycin inhibited the growth of different BTC
cell lines in vitro.
The post-transplant requirement for immunosuppres-
sion appears to facilitate tumor growth. Different studies
have shown that the standard immunosuppressive agents
cyclosporine A and tacrolimus directly intervene in thefter 48 hours of exposure to different dosages of
G2+M phase S phase
Pb Mean ±SE Pb Mean ±SE Pb
39.00 1.33 8.9 0.34
0.001 33.72 0.92 <0.05 5.55 0.43 <0.001
0.001 35.45 0.69 <0.05 4.10 0.16 <0.001
0.001 35.28 0.66 <0.05 4.38 0.30 <0.001
0.001 35.97 0.87 0.09 5.61 0.13 <0.001
0.001 37.67 1.11 0.46 3.21 0.33 <0.001
ycin at doses of 1, 5, 10 and 20 ng/mL, with 5-bromo-20-deoxyuridine and 7-
ents, a typical feature of apoptosis; bt-test was performed; while a Levene test
a: rapamycin; SE: standard error of the mean.
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and resulting in the stimulation of tumor cell growth
and a subsequent increase in the recurrence rate [24,25].
These calcineurin inhibitors act by reducing interleukin-
2 expression, inhibit the early activation of T lympho-
cytes (that is, the transition from the G0 to the G1 phase
of the cell cycle) and promote tumor cell cycle progres-
sion by increasing cdk4 kinase activity [26,27].
Rapamycin acts by inhibiting the mTOR signaling
pathway, as described above. This pathway is already
known to be upregulated in various carcinoma cell lines,
such as lung cancer, renal cancer, ovarian cancer and
breast cancer, as well as in rhabdomyosarcoma, B
lymphoma and osteosarcoma [28,29]. Therefore, this
pathway is of particular interest because of the effective
inhibition function of rapamycin on different BTC cell
lines. Several studies have indeed shown an activated
mTOR pathway in a subset cell line of the liver and an
inhibition of proliferation of neoplastic hepatocytes in
culture, while molecular biological studies, in which dif-
ferent BTC subtypes are examined with various doses of
immunosuppressants, are presently rare [30,31].
The purpose of our study was to examine the inhibiting
effect on tumor cell proliferation of differentiated BTC cell
lines after treatment with rapamycin and the standard im-
munosuppressive therapy. Herein, we show that rapamy-
cin inhibited the growth of two BTC cell lines. The
reduction of the division index occurred almost independ-
ent of the rapamycin doses used; there were marginal dif-
ferences between clinically used doses versus high doses.
Furthermore, rapamycin-treated EGI-1 cells showed a no-
ticeable increase in apoptosis, while the synthesis rate of
both BTC cell lines dropped significantly at the same time.
By contrast, the calcineurin inhibitors cyclosporine A and
tacrolimus induced cell growth in some of the experi-
ments. At all measurement times, immunosuppressant-
treated cell lines showed a higher division index than cells
in untreated control groups. In cell lines treated with cal-
cineurin inhibitors, the reverse pattern was observed, with
these cells exhibiting an increase in rate of synthesis and a
decrease in apoptosis rate.
In summary, our observations suggest that rapamycin
imparts an antiproliferative effect on BTC cells and
therefore might be an advantageous immunosuppressant
for patients after LT due to BTC. However, a uniform
post-transplantation immunosuppression regimen with
rapamycin as a single-agent has not yet been deter-
mined. Thus, a combination of known standard im-
munosuppressive agents with rapamycin appears to be a
more suitable option. The specific combination of these
immunosuppressive agents would then depend on the
type of tumor.
Individual cases have been reported where treatment
with rapamycin led to a black box warning. De novoimmunosuppression with rapamycin after transplant-
ation resulted in disturbed wound healing, artery throm-
bosis and toxicity. The antiproliferative tumor cell effect
of rapamycin demonstrated in this study should still be
considered in post-transplantation immunosuppression
regimens (LT due to liver-originated tumors like BTC).
The first steps in this direction, where a primary therapy
of standard immunosuppressive agents is replaced by
rapamycin for maintenance immunosuppression, have
been undertaken. Rapamycin should not be considered
as a chemotherapeutic agent but it might be helpful for
the prevention of early tumor recurrences after LT [32].
Conclusion
Our results support the hypothesis that rapamycin is a
more suitable immunosuppressant for patients after LT
due to BTC. Future - even in vivo - studies will have to
investigate the ideal combinations of immunosuppres-
sive agents to provide maximal tumor suppression while
ensuring a safe long-term survival free of rejection
episodes.
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